COVID-19-associated pancreatic dysfunction

Abdel‐Moneim, Adel

doi:10.12809/hkmj209056

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the face of such findings, more intensive care should be given to DM patients in case of rapid deterioration. Nevertheless, careful attention should be given to those with nephropathic DM because such patients are at greater risk of viral infection, serious complications, and even death ( 110 , 111 ).…”

Section: Control Of Dm Patients With Covid-19mentioning

confidence: 99%

“…Furthermore, backup from exercise rehabilitation specialists and nutritionists may be needed during a longer period of recovery and hospital stay ( 140 ). Finally, and regarding therapy, although there are different clinical trials and studies ongoing to assess the efficacy and safety of possible therapeutic alternatives, such as the use of chloroquine phosphate, lopinavir/ritonavir, remdesivir, interferon, tocilizumab, ribavirin, and arbidol, among others ( 110 ), no drug against SARS-CoV-2 has been developed and officially approved so far ( 141 ).…”

Section: Control Of Dm Patients With Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review

Beshbishy

Oti

Hussein

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Diabetes mellitus (DM) and coronavirus disease 2019 (COVID-19) are public health issues worldwide, and their comorbidities trigger the progress to severe disease and even death in such patients. Globally, DM has affected an estimated 9.3% adults, and as of April 18, 2021, the World Health Organization (WHO) has confirmed 141,727,940 COVID-19 confirmed cases. The virus is spread via droplets, aerosols, and direct touch with others. Numerous predictive factors have been linked to COVID-19 severity, including impaired immune response and increased inflammatory response, among others. Angiotensin receptor blockers and angiotensin converting enzyme 2 have also been identified as playing a boosting role in both susceptibility and severity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Specifically, in DM patients, both their control and management during this pandemic is herculean as the restriction periods have markedly hampered the maintenance of means to control glycemia, hypertension, and neuroendocrine and kidney diseases. In addition, as a result of the underlyin cardio-metabolic and immunological disorders, DM patients are at a higher risk of developing the severe form of COVID-19 despite other comorbidities, such as hypertension, also potentially boosting the development of higher COVID-19 severity. However, even in non-DM patients, SARS-CoV-2 may also cause transient hyperglycemia through induction of insulin resistance and/or pancreatic β-cell injury. Therefore, a strict glucose monitoring of DM patients with COVID-19 is mandatory to prevent life-threatening complications.

show abstract

Section: Control Of Dm Patients With Covid-19mentioning

confidence: 99%

Section: Control Of Dm Patients With Covid-19mentioning

confidence: 99%

Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review

Beshbishy

Oti

Hussein

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Almutairi F et al (2022) приводят случай наблюдения за пациентом с COVID-19, у которого острый панкреатит развился после разрешения инфекции [168]. [169][170][171][172][173].…”

Section: исследование Liu Et Al (2020) (N=121) показало что уровни ам...unclassified

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

Гриневич

Лазебник

Kravchuk

et al. 2023

jour

View full text Add to dashboard Cite

Summary Post- COVID syndrome refers to the long-term consequences of a new coronavirus infection COVID-19, which includes a set of symptoms that develop or persist after COVID-19. Symptoms of gastrointestinal disorders in post- COVID syndrome, due to chronic infl ammation, the consequences of organ damage, prolonged hospitalization, social isolation, and other causes, can be persistent and require a multidisciplinary approach. The presented clinical practice guidelines consider the main preventive and therapeutic and diagnostic approaches to the management of patients with gastroenterological manifestations of postCOVID syndrome. The Guidelines were approved by the 17th National Congress of Internal Medicine and the 25th Congress of Gastroenterological Scientifi c Society of Russia.

show abstract

AMYLASE CONCENTRATION IN DONOR GROUPS DEPENDING ON TITERS OF ANTI-SARS-CoV-2 IgG IN BLOOD PLASMA

Rachkovska,

Krenytska,

Savchuk

et al. 2023

BTSNUKSB

View full text Add to dashboard Cite

COVID-19 is a disease of the respiratory system; however, some patients experience multiorgan complications, including those of the digestive system. Many studies have focused on liver, bile duct and stomach dysfunctions during the SARS-CoV-2 infection. Currently, it is known that COVID-19 leads to changes in amylase concentration in the blood, which may be a prognostic factor for pancreatic damage; however, information regarding these clinical cases is limited. Our study aimed to determine the potential changes in total amylase, pancreatic amylase and C-reactive protein (CRP) levels in the blood of the donor groups with different titers of anti-SARS-CoV-2 IgG. Donor groups with titers of anti-SARS-CoV-2 IgG 10 ± 3 and 95 ± 5 Index (S/C) were characterized by an increase in total and pancreatic amylase concentrations compared to the donor group with titer of anti-SARS-CoV-2 IgG 0 Index (S/C). We assumed that multiorgan dysfunction developed through the acute inflammatory reactions caused by the SARS-CoV-2 infection. In particular, this may lead to pancreatic complications. To confirm this, we analyzed the CRP concentration in the donor group with the changes in amylase concentration compared to the donor group with titer 0 Index (S/C). The results obtained may be useful in medical practice for diagnosing complications in the post-COVID-19 period and for preventing the development of pancreatic dysfunction during the development of an algorithm for the treatment of COVID-19.

show abstract

COVID-19-associated pancreatic dysfunction

Cited by 3 publications

References 24 publications

Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review

Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

AMYLASE CONCENTRATION IN DONOR GROUPS DEPENDING ON TITERS OF ANTI-SARS-CoV-2 IgG IN BLOOD PLASMA

Contact Info

Product

Resources

About